Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and efficacy of the sequential infusion of allogeneic mesenchymal stem cells (MSC), expanded in vitro with platelet lysate without addition of animal products in the treatment of patients undergoing allo-HSCT who developed one or more cytopenias.

Conditions
-----------------
Cytopenia

Intervention / Treatment
-----------------
* Biological: Sequential infusion of allogeneic mesenchymal stem cells expanded in vitro


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with hematologic malignancies who have been subjected to allo-HSCT and that are diagnosed with one or more peripheral cytopenias with complete chimerism in bone marrow (determined by molecular-STR-studies). They may include: Patients who have received as a source of cells MO or SP Patients who have received cells from a related donor or unrelated HLA-matched Patients transplanted with myeloablative or non-myeloablative conditioning Adequate cardiac function assessed from a clinical point of view by the researcher, with no history of ischemic heart disease (angina or myocardial infarction) in the previous 6 months. Adequate pulmonary function assessed clinically without evidence of severe obstructive or restrictive lung disease. Patients between 18 and 70 years Signed informed consent Exclusion Criteria: Patients whose haemopathy has not been controlled by the transplantation or is in progress at the time of treatment. Patients who do not have complete chimerism in bone marrow (performed within 28 days prior to baseline by molecular study -STR-). Patients with thrombotic microangiopathy. Patients with post-transplant cytopenias with toxic origin in relation to antiviral treatment (eg ganciclovir, valganciclovir) without concomitant graft against host disease. Patients with bacterial, viral or fungal infection that is not being controlled with proper treatment. Patients with a history of ischemic heart disease (angina or myocardial infarction) in the previous 6 months, and those considered by the investigator does not have adequate cardiac function, evaluated from a clinical point of view. Patients with poor lung function, evaluated clinically, according to the researcher. Patients who, in the opinion of the investigator, are not on a good position to tolerate treatment. Patients who do not have the required donor. Women pregnant or at risk of pregnancy by contraceptive measures inadequate. Patients <18 or > 70 years. Patients who did not sign the informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients with cytopenia after allo-HSCT<br>Patients with cytopenia after allo-HSCT | Biological: Sequential infusion of allogeneic mesenchymal stem cells expanded in vitro<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse effects at the time of infusion and infections after infusion of MSC | All the adverse effects that may arise and possible toxicities (WHO grade) after infusion of the cells were collected. | During the period of infusion of the cells into the patient (an average of one hour) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mesenchymal cell efficiency in recovering cytopenia | The efficiency is measured by the recovery of cytopenia after administration of MSC (depending on the original cytopenia) and may be of two types: Complete response: Hb> 10 g / dL Neutrophils> 1500 Million / L Platelets> 100.000 Million / L Maintained at least 7 days Partial response: Hb> 8 and <10 g / dL Neutrophils> 1000 and <1500 Million / L Platelets> 50000 and <100.000 Million / L Maintained at least 7 days | Monitoring will be from the last infusion of MSCs to the patient until 90 days after the last administration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cytopenia